Takashi Saito*†, Atsuo Okamura‡, Junichiro Inoue†, Daisuke Makiura†, Hisayo Doi§, Kimikazu Yakushijin¶, Hiroshi Matsuoka¶, Yoshitada Sakai†#, Rei Ono*
Oncology Research, Vol.27, No.4, pp. 469-474, 2019, DOI:10.3727/096504018X15267574931782
Abstract Chemotherapy-induced peripheral neuropathy (CIPN) frequently occurs in lymphoma patients receiving
R-CHOP, a drug combination therapy. Although severe CIPN may lead to reduction and/or discontinuation
of the medication, predictive factors of CIPN have not been investigated sufficiently to date. We performed
a retrospective exploratory research to determine associations between prevalence of severe CIPN and sociodemographic data, health characteristics, and medical conditions such as anemia at initial diagnosis. Forty
patients (indolent lymphoma, n=9; diffuse large B-cell lymphoma; n=31) received R-CHOP therapy from
September 2009 to July 2014. The median age of patients was 58 years (range=27–76 years). Statistical More >
Login
Register
